A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that significantly improves treatment outcomes and survival in patients with acute myeloid leukemia (AML) with FLT3 gene mutations. The study found that the combined use of the FLT3 inhibitor Quizartinib and the protein synthesis inhibitor Omacetaxine Mepesuccinate (collectively termed QUIZOM) effectively suppresses the growth of cancer cells and activates the patient’s immune system, achieving a composite complete remission (CRc) rate of about 83% while reducing the risk of relapse.
Continue Reading this article here
